2024 ASTRO Annual Meeting Press Kit

The 2024 ASTRO Annual Meeting — the leading meeting in radiation oncology — was held September 29 through October 2 at the Walter E. Washington Convention Center in Washington, DC. Led by ASTRO President Howard Sandler, MD, FASTRO, the meeting was organized around the theme, “Targeting Provider Wellness for Exceptional Patient Care.” New results from clinical trials and other research studies were presented in conjunction with educational panels, keynote addresses and other special sessions. For more information, view our media advisory about the meeting or visit the links below.

• View the briefing recordings from Monday and Tuesday
  
• Meeting Portal – daily schedule, presenter disclosures, abstracts (after embargo lifts), virtual meeting livestream
• Virtual Meeting quick reference – access, support, connection tips

News Briefings

ASTRO news briefings highlighted top-rated abstracts at the Annual Meeting. Links to recordings, study releases, presenter slides and professional photos are below.

Monday, September 30, 10:00 a.m. Eastern time

• Watch the briefing recording
• View/download hi-res photos from the briefing
• View/download presenter slides

• Abstract 1: “A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505),” presented by Matthew Poppe, MD, FASTRO, University of Utah Huntsman Cancer Institute

  • News Release: Post-mastectomy radiation therapy can be shortened by nearly half for patients planning breast reconstruction

• LBA 01: “Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III randomized clinical trial of proton therapy vs IMRT for localized prostate cancer,” presented by Jason Efstathiou, MD, PhD, FASTRO, Massachusetts General Hospital

  • News Release: IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer

• LBA 02: “Concurrent chemoradiation +/- atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005,” presented by Kristin A. Higgins, MD, City of Hope Cancer Center Atlanta

  • News Release: Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer

• LBA 03: “Interim futility results of NRG-HN005, a randomized, phase II/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients,” presented by Sue Yom, MD, PhD, FASTRO, University of California, San Francisco

  • News Release: Existing standard chemoradiation superior to deintensification approaches for HPV-related oropharyngeal cancer

• Moderator: Sameer Keole, MD, FASTRO, Mayo Clinic, ASTRO President-elect

• Outside Experts: Rachel Jimenez, MD, Massachusetts General Hospital, Vice Chair of ASTRO’s forthcoming PMRT guideline update; Kenneth Rosenzweig, MD, Mount Sinai School of Medicine, Chair of ASTRO’s SCLC guideline; Danielle Margalit, MD, MPH, Dana-Farber Cancer Institute, Vice Chair of ASTRO’s oropharyngeal cancer guideline update

Tuesday, October 1, 9:00 a.m. Eastern time

• Watch the briefing recording
• View/download hi-res photos from the briefing
• View/download presenter slides

• Abstract 2: “A prospective, phase II study of 177Lu-Dotatate in patients with surgery- and radiation-refractory meningioma: Results of the WHO grade II/III cohort,” presented by Kenneth Merrell, MD, Mayo Clinic Alix School of Medicine

  • News Release: Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors

• Abstract 150: “Evaluating neurocognitive recovery following stereotactic radiosurgery and whole brain radiation therapy: Insights from a pooled analysis of three phase III trials,” presented by Hua-Ren Ryan Cherng, MD, University of Maryland Medical Center

  • News Release: People who experience side effects from cranial radiation therapy may recover full neurocognitive function within months

• Abstract 215: “Centering Black voices: Factors influencing a cancer patient’s decision to join a clinical trial,” presented by Charlyn Gomez, University of Maryland School of Medicine

  • News Release: Spiritual themes, distrust may factor into Black patients’ reluctance to participate in cancer clinical trials

• Moderator: Andrea K. Ng, MD, MPH, FASTRO, Dana-Farber/Brigham and Women’s Cancer Center, incoming ASTRO Education Council Vice Chair

• Outside Experts: Lia M. Halasz, MD, Fred Hutchinson Cancer Center/The University of Washington, Chair of ASTRO’s CNS Panel; Hyun Kim, MD, Washington University School of Medicine Siteman Cancer Center, ASTRO Radiopharmaceutical Therapy Committee; Chika Madu, MD, Staten Island University Hospital/Northwell Health, Chair of ASTRO’s Community Engagement & Advocacy Committee

For More Information

• For general information about the meeting, visit the ASTRO 2024 FAQs or the Meeting Portal

• For media questions/interview requests, contact ASTRO’s media relations team, Liz Gardner and Jeff White

• For the latest updates from ASTRO, follow us on social media

• For general information on radiation therapy, visit RTAnswers.org